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WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
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• Modelling and simulation based on the
population pharmacokinetic approach
provides estimates of infant exposure to
drugs in breast milk.
• However, complex mechanistic modelling
using both blood and breast milk
concentrations of drug has been
challenging, which makes risk assessment
less complete.

AIMS

WHAT THIS STUDY ADDS

RESULTS

• Applying the population pharmacokinetic
approach to milk concentration data of
fluoxetine (an active parent drug) and
norfluoxetine (an active metabolite), we
show the feasibility of constructing a simple
prediction model for milk concentration
profiles of the parent and active metabolite
without using blood concentration data.

Milk FX and NFX concentration–time profiles were described reasonably well by a one
compartment model with a FX-to-NFX conversion coefficient. Median values of the
simulated relative infant dose on a weight basis (sRID: weight-adjusted daily doses of FX
and NFX through breastmilk to the infant, expressed as a fraction of therapeutic FX daily
dose per body weight) were 0.028 for FX and 0.029 for NFX. The FX sRID estimates were
consistent with those of the plasma/milk-based pop PK model.
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Population pharmacokinetic (pop PK) modelling can be used for PK assessment of drugs in
breast milk. However, complex mechanistic modelling of a parent and an active metabolite
using both blood and milk samples is challenging. We aimed to develop a simple predictive
pop PK model for milk concentration–time profiles of a parent and a metabolite, using data
on fluoxetine (FX) and its active metabolite, norfluoxetine (NFX), in milk.

METHODS
Using a previously published data set of drug concentrations in milk from 25 women
treated with FX, a pop PK model predictive of milk concentration–time profiles of FX and
NFX was developed. Simulation was performed with the model to generate FX and NFX
concentration–time profiles in milk of 1000 mothers. This milk concentration-based pop PK
model was compared with the previously validated plasma/milk concentration-based pop
PK model of FX.

CONCLUSIONS
A predictive pop PK model based on only milk concentrations can be developed for
simultaneous estimation of milk concentration–time profiles of a parent (FX) and an active
metabolite (NFX).

© 2014 The British Pharmacological Society

Population PK of fluoxetine and norfluoxetine in human breastmilk

Introduction
Breastfeeding has major benefits for infants including
reduction in morbidity and mortality, reduction of infection and positive impact on cognitive functions [1–7]. At
present, the reported breastfeeding initiation rate is as
high as 90% in some countries but 66% to 80% of women
receive medications during the post-partum period [8–12].
As a result, there is a high likelihood for the infants to be
exposed to the medications through breast milk. Although
the average amount of most drugs ingested by infants
through breast milk is much less than that received by
mothers even on a body weight adjusted basis [13, 14],
individual variations are poorly understood and cases of
drug toxicity through breast milk are reported (summarized in Drugs and Lactation Database ‘LactMed’) [15].
Pharmacokinetic (PK) assessment of drug excretion
into milk provides important information necessary for
clinical management of breastfeeding women on drugs.
However, conventional PK studies, which require multiple
samples from each participant, are difficult to conduct particularly in this population due to the demanding feeding
schedule and inconvenience for mothers and infants. A
population pharmacokinetic (pop PK) approach with
model-based simulation of a population offers an attractive alternative [16, 17].
Previously, we conducted a proof-of-concept study to
establish a pop PK model of fluoxetine (FX) disposition in
the context of breastfeeding using data of maternal blood
and breast milk samples [17]. This mechanistic model,
however, was not able to account for its active metabolite,
norfluoxetine (NFX), partly due to the imbalance between
the data quantity and the complexity of the physiologically based mechanistic model with multiple blood and
milk compartments.
The objective of this proof-of-concept study was to
develop a simple pop PK model predictive of FX and NFX
milk concentrations without referring to plasma concentrations, thereby negating the need for a complex mechanistic model and intensive PK blood sampling while
allowing simultaneous prediction of a parent drug and its
active metabolite.

Methods
Patients’ data
We used the datasets of FX and NFX concentrations in
milk, which were published elsewhere [17]. These data
were originally retrieved from two previous studies [18,
19], and were de-identified for our purposes. FX treatment
was started at a median of 70 days (range 13–750) [18] and
41 days (range 15–166 days) prior to the study [19], and we
assumed a steady-state. Each of the two studies was
approved by its local ethics committee, and informed
consent was obtained from every participant.

The dataset of breast milk FX and NFX concentrations
in 10 women represented the average concentrations of
the pre- and post-feeding samples [18]. In the remaining
four women in the same study [18], samples were aliquot
parts of milk emptied from both breasts at a given postdose time. The datasets from the other study [19] consisted of milk level data of 10 women: pre-feed samples
(three women), post-feed samples (two women), pooled
samples of pre-feed and post-feed milk (one woman) and
unknown timing (four women).

Pharmacokinetic modelling
Model development and parameter estimation Modelling
was performed using NONMEM® version 7.2 (ICON development solutions). Our base model, which was published
previously [17], addressed FX concentrations in maternal
plasma and milk in a two compartment model, but NFX
concentrations were not accounted for. In the present
analysis, we aimed to describe milk concentrations of
both FX and NFX without referring to maternal plasma
concentrations. To this end, we first modelled FX milk
concentrations using one and two compartment models.
After selecting the best model, the model was expanded
to describe both FX and NFX concentrations in milk.
Model selection was based upon the likelihood ratio
test using minimum objective function values (OFV),
pharmacokinetic parameter estimates and their confidence intervals (CIs), goodness-of-fit plots, and consistency with our previous results [17]. The stochastic
approximation expectation maximization (SAEM) method
with ADVAN 5 subroutine was used in the model
development.
Covariate model Maternal body weight (BW) was examined as a covariate, using a stepwise forward addition.
Each given parameter was log-transformed (θ), and modelled linearly with this covariate (BW), as shown by the
equation θ = θa + θb · BW, where θa is the mean estimate of
population and θb is the deviation due to the covariance.
Improvement of the model with a new covariate was
accepted if there was a significant decrease in the
minimum OFV. A decrease in OFV more than 10.8 (P <
0.001 in chi-square test) was considered to be significant.
Error model Interindividual variabilities were assessed by
exponential error models as follows:

Pi = θ ⋅ e ηi
where Pi is the value of the model parameter for the
ith individual, θ is the population mean estimate for
parameter P and ηi is the normally distributed
interindividual random variability with a mean of zero
and variance ω2.
Br J Clin Pharmacol
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In order to describe the intra-individual variability
(residual error), an exponential error model was used, provided by the equation below:

Yj = Fj ⋅ e εj
where Yj is an observed value of each parameter for the jth
individual, Fj is an individually predicted value, and εj is a
normally distributed random variable with a mean of 0 and
a variance of σ2.
Model validation The final model was evaluated using
both internal and external validation methods. We performed bootstrap with 200 time replacement and repeat
procedure to assess the stability of the final model and CI
of each pharmacokinetic parameter. Visual predictive
check (VPC) was used for assessment of the predictive performance. In order to collect published FX and NFX milk
data for external validation, the MEDLINE database was
searched, with the key words ‘fluoxetine’ and either ‘breast
feeding’ or ‘breast milk’, from 1946 to 2011. Four articles
were eligible for external validation for VPC [20–23]. All
concentration values for VPC were normalized to a 20 mg
maternal dose of FX for the purposes of comparison.
Bootstrap and VPC were performed with NONMEM® and
PLT tools® (version 4.6.7.; “P Less Than”, San Francisco, CA,
USA)
Simulation We took a two stage approach for the simulation. First, based on the final population pharmacokinetic
estimates and variances, fluoxetine milk concentrations at
steady-state were simulated in a population of 1000 individuals. The women’s weight was fixed arbitrarily at 70 kg,
and the maternal dose was fixed at 20 mg every day, a
standard adult dose. Second, using ‘R’ statistical language
(V 2.14.1; R development Core Team 2011. R: A language
and environment for statistical computing. R foundation
for Statistical Computing, Vienna, Austria. ISBN 3-90005107-0, URL http://www.R-project.org), we randomly generated feeding-related parameters with normal distribution
as indicated in the previously published data [24], and
assigned them to each of the simulated infants. The
assigned parameters obtained from the above mentioned
study [24] included feeding numbers per day (mea 11; SD
3), amount of milk ingested at each feeding (mean 76 g per
feeding; SD 12.6 g), feeding intervals (mean 138 min; SD
43 min), and infant age (mean 15.3 weeks; SD 5.9 weeks).
In order to derive the body weight-adjusted FX dose an
infant is predicted to ingest, we needed to assign body
weight to the simulated infants. The above-mentioned
study [24] showed infant ages but no data on body weight
was provided. We thought that estimation of a body
weight solely from the age of the infant without accounting for simulated milk intake amount was likely to introduce unwanted wide variations into the weight-adjusted
920
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dose, because daily milk intake appears to be closely
related to body weight of the infant [25]. Because daily
milk intake per body weight shows relatively tight intraage group variations [25], we took advantage of that
parameter and calculated body weight of each of the
simulated infants as follows. We averaged the milk consumption per body weight in infants of the seven age
groups described in the study (4 weeks to 6 months of age)
[25], which are similar to our simulated infant age range,
and obtained a mean milk intake of 127.5 ml (123.7 g) kg−1
day−1 across the age range. The specific gravity of breast
milk was assumed to be 1.031 [26]. Each infant’s body
weight was calculated by dividing the simulationestimated daily milk intake (ml day−1) with 127.5 ml kg−1
day−1. The mean of the estimated body weight was 5.43 kg
(SD 1.29 kg). For validation purposes, we confirmed that 2
SD of these estimated body weights were within 2 SD of
the age-specific weight data collected in the World Health
Organization (WHO) Multicentre Growth Reference Study
(http://www.who.int/childgrowth/en/).
The results of FX milk concentration and infants’ exposure were compared with our previously published model
which consisted of maternal blood and milk compartments for FX alone [17]. All modelling and simulations
were conducted in NONMEM 7.2, PLT tools, and ‘R’.
Estimation of FX and NFX amount ingested by infants We
converted NFX to FX-equivalent concentrations (ng ml−1)
using their respective molecular weight (FX 309.3 and NFX
295.3), so that the amount of NFX ingested by the infant
can be compared with the maternal FX dose. Therefore,
NFX is expressed as FX-equivalent unless otherwise stated.
The individual infant daily dose of FX or NFX was
derived as follows:
n

Infant daily dose = ∑ Ck ⋅ mvk
k =1

where Ck (ng ml−1) is the simulated FX or NFX concentration at a kth feeding time after administration of FX to the
mother, n is the number of feeds per day, and mvk is the
volume of the milk at a kth feeding (ml). n and mvk of each
simulated infant were derived as described above based
on the published data [24]. Because NFX is an active
metabolite [27], we also calculated the sum of infant dose
of FX and NFX. Because FX undergoes stereoselective
metabolism, and because both enantiomers of NFX may
be less active than FX enantiomers [27–29], we note that
this total FX + NFX is likely to overestimate infant doses,
providing conservative predictions.
The ratio between the infant daily dose per body
weight and the weight-adjusted maternal therapeutic
dose (i.e. 20 mg day−1 for a 70 kg woman is about
0.3 mg kg−1 day−1) was defined as a simulated relative
infant dose (sRID). A sRID was calculated for FX, NFX and
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the sum of both. A sRID ≦ 0.1 (i.e., infant daily dose is
equal, or less than 10% of the maternal therapeutic dose of
FX on a kg body weight basis) served as a reference point
of drug exposure for a breastfed infant [13, 14].

Results

Table 1
Final estimated parameters of the optimal model and bootstrap

Population
mean
estimate
Fixed effects (exp(θ))
Ka (h−1)

Patients’ characteristics
The training data set was the same as our previous article
[17]. The original data [18, 19] from 24 women taking FX
with a mean daily dose of 29.4 mg (range: 7.5–80 mg day−1)
and their 25 breastfeeding infants (one pair of twins) provided 112 breast milk FX and NFX concentration values
that were used in the pop PK analyses. The mean parametric values (± SD) were maternal age, 31.8 ± 5.6 years (range
22.7–44 years), maternal body weight, 64.5 ± 13.5 kg
(range 31–85 kg), infant age, 6.3 ± 6.8 months (range
0.13–25 months) and infant body weight, 5.3 ± 2.1 kg
(range 2.8–10 kg).

Population PK analysis
First, one and two compartment models with absorption
were tested for the prediction of breast milk concentration
of FX. We selected a one compartment model with absorption over a two compartment model, which was not
chosen because the inter-individual variations of parameters could not be estimated. The differential equations of
the model are shown as follows:

dA (FX )
= K a ⋅ Dose − K e ⋅ A (FX )
dt
where Dose is the amount of FX administered per dose per
day, A(FX) is the amount of FX in the compartment, Ka is
an absorption rate constant and Ke is an elimination rate
constant.
Second, we attempted to describe FX and NFX milk
concentrations simultaneously, by expanding the FX one
compartment model (above) to a two compartment
model (i.e. a FX compartment and an NFX compartment).
However, variations of some parameter estimates could
not be reduced to a reasonable level (data not shown).
Given the fact that the observed milk concentration–time
profiles of FX and NFX were similar (Supplementary
Figure S1), an FX-to-NFX conversion coefficient (KFN) was
used instead as a scaling factor:

NFX milk = KFN × FX milk
where NFX milk is NFX concentration in milk, FX milk is FX
concentration in milk, and KFN is the conversion coefficient. Adding absorption lag time did not improve the OFV
and covariates were not found to improve the model fit.

V (l)
CL (l h−1)

0.016
20.5
13.4

RSE(%)*

13.3
3.5
6.9

KFN
1.01
Random effects
Interindividual variability (ω)
111.4
Ka (CV%)
V (CV%)
22.8
CL (CV%)
48.1
KFN
48.1
Residual variability (σ)
FX(CV%)
28.1
NFX(CV%)
29.8

20.2

Bootstrap evaluation
Median 95%CI

0.016
20.3
13.1
0.99

174.2
133.9
64.9
46.8

137.2
84.9
46.7
47.5

58.2
56.1

26.9
29.1

0.0027, 0.041
7.24, 72.0
10.6, 16.7
0.79, 1.2

52.2,
32.4,
36.4,
30.8,

268.2
248.3
58.3
60.7

20.5, 33.8
19.4, 36.3

*RSE: relative standard error (percentage of standard error). KFN FX-to-NFX conversion coefficient.

The final population estimates and variability are presented in Table 1. Goodness-of-fit plots of FX and NFX milk
concentrations (Figure 1) showed that when based on the
model with the population mean parameter estimates, the
concentration data are diversely scattered around the line
of unity in the observation–prediction space (Figure 1A
and B, left panel). Variations were reduced substantially
when model prediction was performed using the individual data (Figure 1A and B, right panel).

Internal and external model validation
Bootstrap Bootstrap results (Table 1) showed that the
parameter values conformed well with those of the population mean, except for the inter-individual variability of
volume of distribution (coefficient of variation of 22.8% vs.
the bootstrap median of 84.9%).
VPC VPC of FX (Figure 2A) and NFX (Figure 2B) in milk
showed good model performance. The model prediction
was also assessed against a data set from published
studies (shown as closed circles in Figure 2), which were
not used for model development. Overall, the internal and
external validation indicates reasonable model performance to predict milk concentrations of FX and NFX.
Simulation Based upon the final pop PK estimates and
variances, FX and NFX concentrations in milk were simulated at steady-state in 1000 women, and infants’ exposure
through breast milk was estimated. As described in the
methods, the average daily milk ingestion of the infants
was estimated to be 127.5 ml kg−1 day−1 [25], and each
infant’s body weight was calculated according to this
weight-adjusted milk intake and the milk intake per day for
each of the simulated infants. The details of infant expoBr J Clin Pharmacol
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Figure 1
Goodness-of-fit plots. The observed milk FX (Figure 1A) and NFX (Figure 1B) concentrations are plotted against the mean population predicted values (left),
and the individually predicted (Post Hoc) predictive values (right). Figure 1C shows weighted residuals of FX (left) and NFX (right)

sure level to FX and NFX are shown in Table 2, and graphically presented in Figure 3.
The simulation yielded a median infant FX exposure of
0.0080 mg kg−1 day−1 (95% CI 0.0077, 0.0083). The median
sRID of FX was 0.028 (95% CI 0.027, 0.029), which was in
close proximity with our previous report (median 0.031;
922
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95% CI 0.030, 0.032) (Figure 3A). The 99th percentile of FX
sRID was 0.083, which means most of the infants were
exposed to less than 8.3 % of maternal dose adjusted by
body weight.
The median infant NFX exposure level was
0.0083 mg kg−1 day−1 (95% CI 0.0079, 0.0088). The 99th

Population PK of fluoxetine and norfluoxetine in human breastmilk

A

FX concentration in milk (ng ml–1)

103
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10

1
0
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Time: post-dose (h)
B

NFX concentration in milk (ng ml–1)

103
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16

Time: post-dose (h)

Figure 2
Visual predictive check (VPC) in FX (panel A) and NFX (panel B). Observed FX or NFX concentrations are shown (white circles) with the median (solid line),
2.5th percentile (lower broken line), and 97.5th percentile predictions from the model. NF or NFX concentrations from the published article are also shown
(black circles). Data points in those articles without specified post-dose sampling time are shown outside the 24 h time frame. Concentrations described as
‘peak’ without specific post-dose time [22] are plotted at 7 h post-dose because a reported average post-dose time of a peak concentration of FX was 6 to
8 h [38]. (A) —, median (model prediction); - - -, 2.5th–97.5th percentile (model prediction); ○, observed FX data (present study); ●, observed FX data from
other studies (external validation). (B) —, median (model prediction); - - -, 2.5th–97.5th percentile (model prediction); ○, observed NFX data (present study);
●, observed NFX data from other studies (external validation)
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Table 2
Simulated infant exposure of FX, NFX and the total of both

FX

NFX (equivalent to FX)

Sum (FX + NFX)

Simulated infant dose through breastfeeding (mg day−1 kg−1)
Range

0.0019 to 0.035

0.0009 to 0.084

0.0034 to 0.11

Median

0.0080

0.0083

0.017

0.0079, 0.0088

0.016, 0.018

0.0032 to 0.29
0.15
0.029
0.028, 0.031

0.012 to 0.37
0.23
0.059
0.057, 0.062

95% CI of median
0.0077, 0.0083
Simulated relative infant dose (fraction of the maternal weight-adjusted dose)
Range
0.0068 to 0.12
99th percentile
0.083
Median
0.028
95% CI of median
0.027, 0.029

percentile of sRID was 0.15. The median of combined
exposure to both FX and NFX was 0.017 mg kg−1 day−1 as
FX equivalents. The 99th percentile of sRID of FX + NFX was
0.23 or 23% of the maternal weight-adjusted FX dose.

Discussion
The first step of a risk assessment of adverse drug effects in
an infant breastfed by a woman on a medication is to
obtain an estimate of the amount of the drug ingested by
the infant. This estimate could be derived from published
data on drug concentrations in milk, multiplied by an
assumed infant milk intake. Although published data are
valuable, they are often based on case reports, and the
derived point estimate of the infant dose through milk
may not accurately reflect actual infant exposure. For
example, the highest reported concentration of the drug
in milk is often used to estimate the infant dose per day.
This intentional overestimate is to provide a ‘worst case’
scenario (i.e. the highest exposure level) by assuming that
the drug concentration in milk remains at the reported
highest level throughout the feeding cycle. However, this
approach generates a dose estimate which significantly
deviates from a population distribution curve of infant
drug exposure levels, potentially jeopardizing risk assessment and clinical decision making.
Lack of large scale studies in this population poses
another challenge. Even if combined, small sample sizes of
published studies make it difficult to estimate variations of
the drug exposure levels in a population of breastfeeding
women and their infants. As a consequence, the likelihood
of infant exposures to a certain level of drug in milk is
difficult to predict. A large scale pharmacokinetic study
with intense sampling provides required information, but
such a study is difficult to conduct in this population. In
this context, a pop PK approach offers an attractive solution because a sparse sampling design can be applied, and
a derived pop PK model can be used for simulation analyses of a population of breastfed infants.
924
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In this proof-of-concept study using FX and NFX
concentration data in milk without referring to plasma
concentrations, we have shown that a relatively simple
non-mechanistic pop PK model may address the parent
(e.g. FX) and its active metabolite (e.g. NFX) disposition in
milk. If the purpose of modelling analyses is to gain insight
into mechanisms of mammary drug disposition, a mechanistic model provides a powerful approach. However, biologically (or physiologically) based models tend to be
complex (i.e. an increasing number of parameters) and
demand datasets which represent multiple compartments
(e.g. blood and milk). On the other hand, if prediction of
drug concentration–time profiles in milk (i.e. infant exposure levels) is the main goal of the modelling analyses,
then a simple, non-mechanistic model based on milk
concentrations can be used without referring to plasma
concentrations. Our present model showed that a nonmechanistic simple model using only milk data (without
maternal blood concentration) could sufficiently estimate
FX excretion into breast milk, and the results were consistent with our previous model with both milk and blood data
[17]. There have been at least two articles published where
excretion into human breast milk of both parent drugs and
their metabolites were estimated by pop PK modelling [30,
31], although in these two studies the mechanistic models
were developed using both maternal plasma and milk concentration data. Whether our approach of using milk concentration profiles to obtain a reasonable prediction
model can be applied to other drugs with active metabolites requires further investigation.
FX is reported to demonstrate non-linear pharmacokinetic profiles in higher dosage [32] which may have
implications in our dose-standardized VPC (Figure 2).
However, the mean FX dose in the dataset (29.4 mg day−1)
is relatively low. Therefore, it is unlikely that FX shows nonlinear pharmacokinetics in this population, justifying our
dose-standardized VPC.
Both FX and NFX concentrations in milk are approximately 1.5 to 2 times higher in post-feed than in pre-feed
samples [18]. In our dataset, milk concentrations used for
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Figure 3
A histogram of simulated relative infant dose (sRID) of FX, NFX, and FX + NFX. One thousand infants were simulated using the final model with randomly
assigned feeding parameters according to characteristics of milk intake of infants aged between 4 weeks and 6 months [24, 25]. The simulation results are
shown as the probability distribution of infant exposure levels in the form of a histogram of sRID of FX (panel A), NFX (panel B), and FX+NFX (panel C). sRID
is a dose the infant would ingest per day, which is expressed as % of the standard dose kg−1 of the mother (see Methods). Median (open triangles) and 99th
percentile values (closed triangles) of sRID were also shown. NFX results were converted to FX equivalent on a molar basis. In Figure 3A, FX simulation results
are shown with a histogram of the previous study [17], which was based on a model of blood and milk FX concentrations. (A) , present study; , median
(2.8%); , 99th percentile (8.3%);
, Panchaud et al. [17]. (B) , median (2.9%); , 99th percentile (15.0%). (C) , median (5.9%); , 99th percentile (23.0%)
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the modelling analyses included mainly averages of preand post-feed milk levels, aliquot concentrations, and
those determined in pre- or post-feed samples [18, 19].
Therefore, the milk concentration data are unlikely to be
biased in one particular direction (i.e., pre- or post-feeding
samples). Nevertheless, standardization of sampling
timing is important to design a study of drug excretion
into milk. FX is metabolized to NFX mainly by CYP2D6 [33].
Both FX and NFX are known to have antidepressant activity [27]. FX is a racemic mixture (1:1) of R-fluoxetine and
S-fluoxetine enantiomers [34], and is metabolized to
R-norfluoxetine and S-norfluoxetine. Both in animal
and human studies, S-norfluoxetine, R-fluoxetine and
S-fluoxetine act equally [27–29]. On the other hand,
R-norfluoxetine is significantly less potent than these three
enantiomers [27–29]. In this simulation, we conservatively
assumed that the activity of NFX was higher than that
reported in animal studies (i.e. we assumed that the activity ratio of NFX to FX is 1:1). Based on this assumption, we
calculated a sum of FX and NFX in milk, which showed that
the 99th percentile of sRID (FX + NFX) was relatively high
(23% of the maternal weight-adjusted dose), although the
median was 5.9%. Our model predicts that infant doses of
NFX (Figure 3B) are similar to those of FX (Figure 3A),
causing combined doses of FX and NFX (Figure 3C) to be
approximately two-fold higher than each of the FX and
NFX doses. In theory, intake of this dose range of FX and
NFX for a prolonged period of time may result in steadystate plasma concentrations at near therapeutic concentrations in individuals with significantly reduced clearance.
Whether this happens in infants is not clear, as ontogeny of
FX and NFX clearance has not been fully revealed.
There are several limitations and challenges in this
study: First, our sample size was relatively small. A pop PK
approach requires large numbers of subject to develop
a valid model and address interindividual variations.
Because we used data from previous studies, only 24
mothers with 25 infants were available. This is a relatively
small sample size, potentially increasing uncertainty of
parameter estimates. Secondly, the model did not take
into account maternal pharmacogenomic aspects of FX
metabolism. PK modelling of drugs metabolized by
CYP2D6, which is characterized by large inter-individual
differences in function due to genetic polymorphism,
requires information on genetic variants, which was not
available in our dataset. The maternal CYP2D6 genotype
information may improve the model performance. On the
other hand, CYP2D6 genotypes are less likely to play a
major role in neonates and infants, because their CYP2D6
function is poorly developed [35]. Third, relative paucity of
data on CYP2D6 development [36, 37] poses a challenge
when estimated infant drug intake (Figure 3) is interpreted. In this study, we provide estimated distributions
of the infant doses, which have different implications
depending on infant drug metabolizing capacities.
Because the activity of CYP2D6 may be as low as 20% of
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the adult level in 8 to 30-day-old infants [35–37], clearance
of FX in infants may be low as well. Similarly, NFX clearance
in neonates and infants, which is mainly through
glucuronidation, may be lower than adults due to its
developmental process. However, data on FX and NFX
clearance in infants are lacking.
Despite these limitations and challenges, our approach
opens a door to pop PK analyses to predict concentrations
of other drugs with active metabolites in human milk. To
validate this approach, prospective studies of model
development and validation will be needed.
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Figure S1
The observed concentrations of FX and NFX in each
patient. FX and NFX concentration–time profiles in milk
were largely similar

